Skip to content
Menu

Maze Therapeutics Q3 EPS $(0.79) Misses $(0.77) Estimate

Benzinga Newsdesk 1 week ago

NewsEarningsEarnings Misses

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.77) by 2.6 percent. This is a 19.7 percent decrease over losses of $(0.66) per share from

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.77) by 2.6 percent. This is a 19.7 percent decrease over losses of $(0.66) per share from the same period last year.

Read at benzinga.com